Daniel M. Skovronsky
Net Worth
Last updated:
What is Daniel M. Skovronsky net worth?
The estimated net worth of Dr. Daniel M. Skovronsky is at least $67,938,873 as of 1 Feb 2024. He owns shares worth $52,958,873 as insider and has received compensation worth at least $14,980,000 in Eli Lilly and Company.
What is the salary of Daniel M. Skovronsky?
Dr. Daniel M. Skovronsky salary is $2,140,000 per year as Senior Vice President, Chief Scientific Officer & Pres of Lilly Research Labs in Eli Lilly and Company.
How old is Daniel M. Skovronsky?
Dr. Daniel M. Skovronsky is 51 years old, born in 1974.
What stocks does Daniel M. Skovronsky currently own?
As insider, Dr. Daniel M. Skovronsky owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Eli Lilly and Company (LLY) | Senior Vice President, Chief Scientific Officer & Pres of Lilly Research Labs | 75,818 | $698.5 | $52,958,873 |
What does Eli Lilly and Company do?
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Daniel M. Skovronsky insider trading
Eli Lilly and Company
Eli Lilly and Company key executives
Eli Lilly and Company executives and other stock owners filed with the SEC:
- Dr. Daniel M. Skovronsky (51) Senior Vice President, Chief Scientific Officer & Pres of Lilly Research Labs
- Mr. David A. Ricks (57) Chairman, Chief Executive Officer & Pres
- Ms. Anat Hakim J.D. (56) Senior Vice President, Gen. Counsel & Sec.